News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
717,055 Results
Type
Article (43137)
Company Profile (437)
Press Release (673481)
Multimedia
Podcasts (81)
Webinars (13)
Section
Business (209076)
Career Advice (2022)
Deals (36092)
Drug Delivery (106)
Drug Development (84382)
Employer Resources (173)
FDA (16554)
Job Trends (15123)
News (354094)
Policy (33209)
Tag
Academia (2659)
Accelerated approval (6)
Adcomms (26)
Allergies (88)
Alliances (51130)
ALS (94)
Alzheimer's disease (1434)
Antibody-drug conjugate (ADC) (144)
Approvals (16542)
Artificial intelligence (269)
Autoimmune disease (25)
Automation (16)
Bankruptcy (373)
Best Places to Work (11857)
BIOSECURE Act (20)
Biosimilars (108)
Biotechnology (330)
Bladder cancer (84)
Brain cancer (28)
Breast cancer (293)
Cancer (2351)
Cardiovascular disease (191)
Career advice (1690)
Career pathing (30)
CAR-T (159)
Cell therapy (447)
Cervical cancer (20)
Clinical research (68456)
Collaboration (882)
Compensation (539)
Complete response letters (24)
COVID-19 (2655)
CRISPR (45)
C-suite (252)
Cystic fibrosis (105)
Data (2234)
Decentralized trials (2)
Denatured (28)
Depression (50)
Diabetes (277)
Diagnostics (6440)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (127)
Drug pricing (108)
Drug shortages (26)
Duchenne muscular dystrophy (100)
Earnings (87922)
Editorial (41)
Employer branding (21)
Employer resources (147)
Events (116291)
Executive appointments (743)
FDA (17826)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (783)
Gene editing (113)
Generative AI (20)
Gene therapy (328)
GLP-1 (757)
Government (4525)
Grass and pollen (4)
Guidances (59)
Healthcare (19171)
Huntington's disease (24)
IgA nephropathy (31)
Immunology and inflammation (133)
Indications (30)
Infectious disease (2800)
Inflammatory bowel disease (146)
Inflation Reduction Act (11)
Influenza (52)
Intellectual property (99)
Interviews (311)
IPO (16828)
IRA (43)
Job creations (3709)
Job search strategy (1435)
Kidney cancer (11)
Labor market (38)
Layoffs (503)
Leadership (18)
Legal (8001)
Liver cancer (78)
Lung cancer (333)
Lymphoma (155)
Machine learning (7)
Management (58)
Manufacturing (314)
MASH (69)
Medical device (13528)
Medtech (13533)
Mergers & acquisitions (19803)
Metabolic disorders (721)
Multiple sclerosis (85)
NASH (19)
Neurodegenerative disease (102)
Neuropsychiatric disorders (33)
Neuroscience (2008)
NextGen: Class of 2025 (6760)
Non-profit (4555)
Now hiring (39)
Obesity (388)
Opinion (226)
Ovarian cancer (78)
Pain (91)
Pancreatic cancer (84)
Parkinson's disease (155)
Partnered (21)
Patents (238)
Patient recruitment (112)
Peanut (48)
People (58732)
Pharmaceutical (87)
Pharmacy benefit managers (19)
Phase I (21485)
Phase II (30170)
Phase III (22361)
Pipeline (1215)
Policy (147)
Postmarket research (2632)
Preclinical (9205)
Press Release (67)
Prostate cancer (113)
Psychedelics (37)
Radiopharmaceuticals (263)
Rare diseases (405)
Real estate (6020)
Recruiting (66)
Regulatory (22849)
Reports (46)
Research institute (2426)
Resumes & cover letters (351)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (76)
Series A (139)
Series B (90)
Service/supplier (11)
Sickle cell disease (57)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (30)
Startups (3768)
State (2)
Stomach cancer (16)
Supply chain (69)
Tariffs (39)
The Weekly (51)
Vaccines (708)
Venture capitalists (43)
Weight loss (258)
Women's health (37)
Worklife (17)
Date
Today (176)
Last 7 days (882)
Last 30 days (2693)
Last 365 days (33938)
2025 (10936)
2024 (36419)
2023 (41131)
2022 (52433)
2021 (56877)
2020 (55018)
2019 (47517)
2018 (35797)
2017 (33189)
2016 (32486)
2015 (38532)
2014 (32328)
2013 (27245)
2012 (29335)
2011 (29974)
2010 (28150)
Location
Africa (737)
Alabama (58)
Alaska (7)
Arizona (240)
Arkansas (14)
Asia (39546)
Australia (6577)
California (6249)
Canada (2023)
China (538)
Colorado (272)
Connecticut (288)
Delaware (149)
Europe (86577)
Florida (922)
Georgia (206)
Idaho (57)
Illinois (553)
India (25)
Indiana (310)
Iowa (12)
Japan (164)
Kansas (107)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (908)
Massachusetts (4747)
Michigan (221)
Minnesota (399)
Mississippi (2)
Missouri (83)
Montana (29)
Nebraska (25)
Nevada (63)
New Hampshire (67)
New Jersey (1758)
New Mexico (30)
New York (1761)
North Carolina (1033)
North Dakota (8)
Northern California (2703)
Ohio (206)
Oklahoma (14)
Oregon (38)
Pennsylvania (1396)
Puerto Rico (12)
Rhode Island (34)
South America (1113)
South Carolina (22)
South Dakota (1)
Southern California (2330)
Tennessee (101)
Texas (924)
United States (23676)
Utah (184)
Virginia (149)
Washington D.C. (63)
Washington State (573)
West Virginia (3)
Wisconsin (55)
717,055 Results for "inhibitor therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Accent Therapeutics Presents Data Supporting Therapeutic Potential of First-in-Class DHX9 Inhibitor, ATX-559, and Novel KIF18A Inhibitor, ATX-295, at the AACR Annual Meeting 2025
April 28, 2025
·
6 min read
GLP-1
GLP-1 Drug Boom Recalls the Rise of PD-1 Checkpoint Inhibitors
The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences suggest history may not repeat itself.
March 19, 2025
·
8 min read
·
Ben Hargreaves
Press Releases
ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status
April 24, 2025
·
7 min read
Press Releases
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure
April 30, 2025
·
9 min read
Press Releases
Nimbus Therapeutics Announces Initiation of First-in-Human Clinical Trial with NDI-219216, Novel WRN Inhibitor for MSI-H Tumors
April 28, 2025
·
4 min read
Press Releases
BlossomHill Therapeutics to Present the Design and Discovery of BH-30643, the Company’s OMNI-EGFR™ Inhibitor, at the 2025 AACR Annual Meeting
April 3, 2025
·
3 min read
Press Releases
Quanta Therapeutics Presents Late-Breaking Data for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, at AACR Annual Meeting 2025
April 28, 2025
·
5 min read
Press Releases
ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson’s Disease
April 30, 2025
·
7 min read
Press Releases
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
April 28, 2025
·
9 min read
Press Releases
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
March 19, 2025
·
7 min read
1 of 71,706
Next
